Orthopediatrics Corp (KIDS) Given Consensus Rating of “Buy” by Brokerages

Shares of Orthopediatrics Corp (NASDAQ:KIDS) have earned a consensus recommendation of “Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $27.00.

A number of equities analysts have issued reports on the company. BidaskClub cut Orthopediatrics from a “buy” rating to a “hold” rating in a report on Thursday. Zacks Investment Research cut Orthopediatrics from a “buy” rating to a “hold” rating in a report on Saturday, November 3rd.

In other news, Director Kevin Unger sold 1,000 shares of the firm’s stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $33.22, for a total value of $33,220.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Daniel J. Gerritzen sold 9,525 shares of the firm’s stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $33.73, for a total value of $321,278.25. The disclosure for this sale can be found here. 46.10% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sei Investments Co. bought a new position in shares of Orthopediatrics in the 2nd quarter valued at about $126,000. Rhumbline Advisers bought a new position in shares of Orthopediatrics in the 3rd quarter valued at about $207,000. Regal Investment Advisors LLC bought a new position in shares of Orthopediatrics in the 3rd quarter valued at about $246,000. Indiana Trust & Investment Management CO bought a new position in shares of Orthopediatrics in the 3rd quarter valued at about $248,000. Finally, Paradigm Capital Management Inc. NY bought a new position in shares of Orthopediatrics in the 2nd quarter valued at about $280,000. Institutional investors own 40.22% of the company’s stock.

KIDS stock traded down $0.83 during trading hours on Monday, reaching $28.88. 28,673 shares of the stock were exchanged, compared to its average volume of 44,486. The stock has a market cap of $380.76 million and a PE ratio of -5.07. The company has a current ratio of 5.67, a quick ratio of 3.23 and a debt-to-equity ratio of 0.62. Orthopediatrics has a 12 month low of $14.00 and a 12 month high of $39.81.

Orthopediatrics (NASDAQ:KIDS) last released its earnings results on Wednesday, October 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03). The firm had revenue of $15.82 million for the quarter, compared to the consensus estimate of $15.19 million. Orthopediatrics had a negative return on equity of 65.26% and a negative net margin of 55.97%. Orthopediatrics’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter last year, the company posted ($1.70) EPS. On average, analysts forecast that Orthopediatrics will post -0.95 earnings per share for the current fiscal year.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.

Read More: NASDAQ Stock Market Explained

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply